We are live on ! Find out more
GTC

Ghost Tree Capital Portfolio holdings

AUM $331M
1-Year Est. Return 70.11%
This Fund
S&P 500
This Quarter Est. Return
+10.87%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$309M
AUM Growth
+$30.5M
Cap. Flow
+$16.2M
Cap. Flow %
5.24%
Top 10 Hldgs %
34.98%
Holding
101
New
36
Increased
15
Reduced
14
Closed
32

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$12M
2
ENDP
Endo International plc
ENDP
+$10.4M
3
ISRG icon
Intuitive Surgical
ISRG
+$10.1M
4
ALXN
Alexion Pharmaceuticals
ALXN
+$8.63M
5
GNMK
GenMark Diagnostics, Inc
GNMK
+$7.56M

Top Sells

Rank Stock Value
1
ZBH icon
Zimmer Biomet
ZBH
+$11.8M
2
CYH icon
Community Health Systems
CYH
+$7.84M
3
ZSPH
ZS PHARMA INC COMS TK (DE)
ZSPH
+$6.94M
4
CELG
Celgene Corp
CELG
+$6.92M
5
DYAX
DYAX CORPORATION
DYAX
+$5.86M

Sector Composition

Rank Sector Weight
1 Healthcare 85.5%
2 Financials 1.65%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PBYI icon
51
Puma Biotechnology
PBYI
$434M
$2.04M 0.66%
17,500
-12,500
-42% -$2.26M
TNXP icon
52
Tonix Pharmaceuticals
TNXP
$198M
– –
0
– –
RDUS
53
DELISTED
Radius Health, Inc.
RDUS
$1.69M 0.55%
25,000
-50,000
-67% -$2.33M
ARAV
54
DELISTED
Aravive, Inc. Common Stock
ARAV
$1.52M 0.49%
+16,667
New +$1.69M
ADAP
55
DELISTED
Adaptimmune Therapeutics
ADAP
$1.41M 0.46%
+76,850
New +$1.32M
ASND icon
56
Ascendis Pharma A/S
ASND
$17.1B
$1.13M 0.37%
+63,739
New +$1.12M
UNIS
57
DELISTED
Unilife Corporation
UNIS
$968K 0.31%
45,000
– –
VCYT icon
58
Veracyte
VCYT
$4.72B
$873K 0.28%
+78,386
New +$772K
BDSI
59
CALL
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$845K 0.27%
106,200
-93,800
-47% -$806K
ALPN
60
DELISTED
Alpine Immune Sciences Inc
ALPN
$758K 0.25%
+12,500
New +$745K
BCRX icon
61
BioCryst Pharmaceuticals
BCRX
$2.36B
$672K 0.22%
+45,000
New +$512K
KIN
62
DELISTED
Kindred Biosciences, Inc.
KIN
$638K 0.21%
93,500
-7,000
-7% -$49.7K
BIOL
63
DELISTED
Biolase, Inc.
BIOL
$522K 0.17%
24
– –
XOMA
64
DELISTED
Xoma
XOMA
$485K 0.16%
6,250
+2,650
+74% +$191K
OCRX
65
DELISTED
Ocera Therapeutics, Inc.
OCRX
$475K 0.15%
125,000
– –
GKOS icon
66
Glaukos
GKOS
$9.21B
$435K 0.14%
+15,000
New +$436K
XENE icon
67
Xenon Pharmaceuticals
XENE
$6.6B
$432K 0.14%
+37,500
New +$518K
EVFM
68
DELISTED
Evofem Biosciences, Inc. Common Stock
EVFM
$387K 0.13%
+478
New +$307K
ADVM
69
DELISTED
Adverum Biotechnologies
ADVM
$244K 0.08%
1,500
-9,500
-86% -$3.21M
A icon
70
CALL
Agilent Technologies
A
$37.1B
– –
-100,000
Closed -$4.16M
ABBV icon
71
AbbVie
ABBV
$450B
– –
-70,000
Closed -$4.1M
ACAD icon
72
Acadia Pharmaceuticals
ACAD
$4.38B
– –
-120,000
Closed -$3.91M
BDX icon
73
Becton Dickinson
BDX
$43.6B
– –
-35,875
Closed -$5.03M
BLUE
74
DELISTED
bluebird bio
BLUE
– –
-2,316
Closed -$3.62M
BMRN icon
75
BioMarin Pharmaceuticals
BMRN
$11.5B
– –
-35,000
Closed -$4.36M
1 2
3
4

Similar funds

SF
Susquehanna Foundation Bala Cynwyd, Pennsylvania $333M AUM 35.73% 1-Year Est. Return
AFS
Annapolis Financial Services Annapolis, Maryland $338M AUM 23.49% 1-Year Est. Return
SFA
Source Financial Advisors New York $338M AUM 33.62% 1-Year Est. Return
E
ETFidea Syracuse, New York $316M AUM 29.57% 1-Year Est. Return
OHCM
Oak Hill Capital Management New York $310M AUM 17.23% 1-Year Est. Return
MC
Minot Capital Broomfield, Colorado $353M AUM 25.25% 1-Year Est. Return
BRA
Biechele Royce Advisors Fishers, Indiana $303M AUM 20.64% 1-Year Est. Return
S
Syntrinsic Denver, Colorado $301M AUM 27.27% 1-Year Est. Return

Ghost Tree Capital's Q2 2015 Portfolio in Review

As of Q2 2015, Ghost Tree Capital held 101 positions worth $309M, up 11% from $278M the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Ghost Tree Capital deployed $16.2M of net new capital in Q2 2015, opening 36 new positions and adding to 15 existing holdings. Its largest new stake was Biogen: 30,000 shares worth $12.1M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 72% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Sage Therapeutics, an estimated $4.02M trimmed.

  • Ghost Tree Capital's largest Q2 2015 buy was Biogen: 30,000 shares worth $12.1M.
  • Ghost Tree Capital added most to Five Prime Therapeutics, Inc. in Q2 2015, an estimated $7.24M increase.
  • Ghost Tree Capital's biggest Q2 2015 reduction was Sage Therapeutics, cutting an estimated $4.02M.
  • Ghost Tree Capital fully exited Zimmer Biomet in Q2 2015, selling an estimated $11.8M.
  • Ghost Tree Capital's ten largest holdings make up 35% of its $309M portfolio in Q2 2015.
  • Ghost Tree Capital opened 36 new positions and closed 32 in Q2 2015.
  • Ghost Tree Capital's portfolio value rose 11% quarter-over-quarter to $309M.

Based on Ghost Tree Capital's 13F filing for Q2 2015, filed 14 Aug 2015.